Influence of information provided prior to switching from Humira to biosimilar adalimumab on UK patients' satisfaction: a cross-sectional survey by patient organisations.
Kayoko KanekoDaniel Prieto AlhambraClare JacklinAilsa BosworthSally DickinsonSarah BerryHelen McAteerPeter C TaylorPublished in: BMJ open (2022)
Patient reported experiences of the process of switching from originator to biosimilar emphasise the importance of clear communication, training and information in order to optimise perception and maximise achievable outcomes with the new treatment.
Keyphrases
- patient reported
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- rheumatoid arthritis
- peritoneal dialysis
- mental health
- healthcare
- metabolic syndrome
- adipose tissue
- systemic lupus erythematosus
- patient reported outcomes
- juvenile idiopathic arthritis
- insulin resistance
- replacement therapy